VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Waxman on Advancements in Acute Promyelocytic Leukemia

Samuel Waxman, MD
Published: Wednesday, Nov 11, 2015



Samuel Waxman, MD, Distinguished Service Professor of Medicine, Hematology and Medical Oncology, Distinguished Service Professor of Oncological Sciences, Mount Sinai Health System, discusses advancements in treating patients with acute promyelocytic leukemia (APL).

APL went from being a 100% fatal disease to being 95% curable, Waxman explains. Over years of studying the disease, there has been a novel concept in treating APL, a leukemia now known to be treatable with two minimally toxic agents, known as all trans retinoic acid and arsenic trioxide. In combination alone, without chemotherapy, it is predicted that more than 85% to 90% of patients can be treated.

Another interesting characteristic of treating APL, Waxman says, is that therapy can be administered to patients of varying ages with equal efficacy and without toxicities associated with chemotherapy.

<<< View more from the 2015 CFS Annual Meeting



Samuel Waxman, MD, Distinguished Service Professor of Medicine, Hematology and Medical Oncology, Distinguished Service Professor of Oncological Sciences, Mount Sinai Health System, discusses advancements in treating patients with acute promyelocytic leukemia (APL).

APL went from being a 100% fatal disease to being 95% curable, Waxman explains. Over years of studying the disease, there has been a novel concept in treating APL, a leukemia now known to be treatable with two minimally toxic agents, known as all trans retinoic acid and arsenic trioxide. In combination alone, without chemotherapy, it is predicted that more than 85% to 90% of patients can be treated.

Another interesting characteristic of treating APL, Waxman says, is that therapy can be administered to patients of varying ages with equal efficacy and without toxicities associated with chemotherapy.

<<< View more from the 2015 CFS Annual Meeting




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x